Reddit Posts
Promising upsides on these biotech penny stocks
SABS/SABSW and BARDA Strategic Plan for 2022-2026
$HCCC Alpha Tau DD: Warrants are risky, but the reward is potentially sky-high and their technology could save countless lives from cancer
$SABS shows effectiveness against Omicron variant. Eli Lilly and Regeneron do not
$SABS The Solution to Future Covid-19 Variants, Backed by the US gov
Black Friday... All my stocks are on sale right now, except from SABS - 20% up at opening...
SABS update? 10% spike randomly occurred about 15 minutes ago.
Mentions
So what’s going to be tomorrow’s DeSpac runner? The last 3 have been stunning, but out of left field, except they were all in the Pharma/biotech area. Are there any that haven’t ran yet? YS, ZURA, CDT, SABS, NUVB, CDT are former spacs, did I miss any? Has anybody seen a pattern?
SABS for me. I don’t care about the $, but I feel the company deserves better than to just limp along. Even after reverse split it keep going down.
[SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split effective on January 5, 2024](https://www.globenewswire.com/news-release/2024/01/02/2802947/0/en/SAB-Biotherapeutics-Announces-1-for-10-Reverse-Stock-Split.html) \- SABS SABSW
SABS filed preliminary motion for a special meeting to vote to give the board authority to execute reverse stock split within a year. Hopefully it won’t come to it https://capedge.com/filing/1833214/0000950170-23-069098/SABS-PRE14A (1) to authorize the Company’s Board, in its discretion but prior to the one-year anniversary of the date on which the proposal is approved by the Company’s stockholders at the Special Meeting, to amend our amended and restated certificate of incorporation to effect a reverse stock split of all of the outstanding shares of our Common Stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 2-for-3 to 1-for-10, with such ratio to be determined by the Board (the “Reverse Stock Split Proposal” or “Proposal 1”); and (2) to transact such other business as may properly come before the Special Meeting or any adjournments thereof.
[SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes](https://www.globenewswire.com/news-release/2023/11/29/2787640/0/en/SAB-Biotherapeutics-Announces-Commencement-of-the-HUMAN-Phase-1-Clinical-Trial-with-SAB-142-a-Potential-Disease-Modifying-Treatment-for-Type-1-Diabetes.html) \- SABS SABSW
Not SABS relate but still biotech- are you following OABI by chance?
SABS added new board member and it looks bullish AF. Not farting around on the push forward with the T1 diabetes cure. https://ir.sab.bio/news-releases/news-release-details/sab-biotherapeutics-appoints-katie-ellias-board-directors/
[SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates](https://www.globenewswire.com/news-release/2023/11/14/2779939/0/en/SAB-Biotherapeutics-Announces-Q3-2023-Financial-Results-and-Provides-Company-Updates.html) \- SABS SABSW [SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes](https://www.globenewswire.com/news-release/2023/11/14/2779962/0/en/SAB-Biotherapeutics-Announces-Completion-of-67-1-Million-Financing-to-Advance-Potential-Disease-Modifying-Treatment-for-Type-1-Diabetes.html)
Exited my NRXP commons that I bought pretty low for a decent slow climb up and gains. Never did pull the trigger on that LAB M and A. Wanted a piece of RKLB and LILM, but am loathe to spend cash. But I think that LILM will run in a month. I’m just in the ARIZR and BRKHW now. I’m willing to lose what I have staked in those two if they liquidate. Feel content with my remaining few tickers. Wish I were holding commons instead of warrants on that SABS. But I have an ungodly amount of SABS warrants and that’s just how it works if I don’t want to be overweight on that. Been doing ok with some infrequent smash and grabs by dumping a ton of cash in at once and quickly exiting. I’m waiting for Santa Rally and H22024. Then I think I’ll be making some jack again. More time than money.😉GLTA, happy Friday.
SABS proxy vote to increase float. I don't know enough about anything to untangle it, but FYI.
SABS coming back from the dead. Love to see it. I’m glad they bought more time. But, to be fair I have been in it a very long time and can’t really remember a time when I wasn’t like: another year or two… 😅
SABS gets a little love today. Phase one initiated on the type one diabetes cure. Up about 22%
Checked out the SABS investor presentation, and it seems that they’ve fully pivoted to SAB142, which is their approach to prevent/delay type 1 Diabetes. This is logical as the announcement of up to $130m in funding to see this through to phase 2 seems to be specific for this program. What are you guys’ thoughts on what’s going to happen with their influenza (SAB176) and CDI (SAB195) programs. Will they still be able to develop/pursue these in parallel, or do we think those are on pause given the specific investment tied to SAB142? The influenza program was fast tracked/breakthrough so it seems like they are close(r) and would be a waste to pause that now. Would they need specific funding now, or can they develop that on the side? https://ir.sab.bio/static-files/b332c893-5795-4d05-af96-a9ebcd917f24
[SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes](https://www.globenewswire.com/news-release/2023/10/02/2752666/0/en/SAB-Biotherapeutics-Announces-Private-Placement-of-up-to-130-Million-to-Advance-Development-of-Lead-Drug-Candidate-for-Type-1-Diabetes.html) \- SABS SABSW
Everyday I browse this sub like it’s the obituary section in The NY Times, dreading to find out if SABS has finally bought the firm.
Just took a peek at my SABS. It’s pretty cool that they have never sold any insider shares. Pretty unusual for a SPAC. So, I will take that as a positive. Have a great day! 😊🌞
Good morning 🌞 I reviewed my port over the long weekend. Out of 15 tickers, 7 are current or former SPACs. 10,000 ARIZR @ .09 C/B 900 BTDR with 900+% gains. Not selling. 33,294 DNA $1.82 C/B. Not selling. 100 SABS C/B $.79. Not selling. 10,000 SABSW C/B $.12 Not selling. 4000 BRKHW C/B $.017 10,000 KRNLW C/B $.11 GLTA! Just a minnow, but in it to win it.
It relates to this S3. “Up to 1,916,894 Shares of Common Stock SAB Biotherapeutics, Inc. This prospectus relates to up to 1,916,894 shares of common stock, par value $0.0001 per share, that the selling securityholder identified in this prospectus may sell from time to time in one or more transactions in amounts, at prices and on terms that will be determined at the time of the offering. The shares of common stock being offered for resale include up to 1,916,894 shares of common stock (the “Shares”), that were initially issued pursuant to an agreement with Ladenburg Thalmann & Co. Inc. We issued such Shares to the selling securityholder in a transaction not involving any public offering. See the section entitled “Selling Securityholder” in this prospectus.” https://capedge.com/filing/1833214/0001437749-23-024291/SABS-S3
Did you see this weird effect filing for SABS? I don’t know what it means. https://ir.sab.bio/sec-filings/sec-filing/effect/9999999995-23-002536/
SABS essentially announced they would be diluting again very soon in the last earnings release, so barring an unexpected announcement of some *very* positive development, it doesn't look good. "[Financial Guidance](https://www.globenewswire.com/news-release/2023/08/21/2728659/0/en/SAB-Biotherapeutics-Provides-Company-Update-for-Q2-2023-Financial-Results.html#:~:text=2023%20Financial%20Results-,Financial%20Guidance,-%3A%20Based%20on): Based on its current operating plans, SAB reaffirms that it expects its existing business plan, cash and cash equivalents, and anticipated cash flows will be sufficient to fund its operating expenses and capital expenditure requirements ***through October 2023***."
SABS, could you just not do this? SMH. Hurricane coming. 🤡 moved further north, now in direct line of Spaghetti models. Rare location. I must be a magnet. 🤡🤡🤡😅😁😬 mayhem. Kitties, especially the Tortie looking wild eyed. They know. Mega moon and big storm ⛈️ bearing down on us. Just wait and see. Prepared. As much as one can be. ✊
SABSW was low volume, it was neither the Rise nor the Dawn of the Planet of the SABS…one day…
I’m up 908% on that Bitdeer. Not selling. Cannot wait for the halvening in H2 2024. Why SABS, ARIZR, up so much today? Was my first day of school. Surprised. Anyone heard from Slammerbar? I can’t remember if he was on Maui. Worried. I didn’t realize the fire was that serious. Hopefully he’s ok.
Hadn’t look at my SABS news or stuff in a while, because well… bag holding… went on stocktwits. They are such an upbeat group! Totally wholesome and realistic. Some of those stocktwits boards are full of really unhinged weirdos. SABS. We like the cows. 🐄🐄🐄😁
What's the next MLTX ? Went to $100 now at $50 SABS?
That link is for a **S-3** registration statement, [filed May 9, effective May 17](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-271768&owner=exclude&count=40). "[SAB Biotherapeutics, Inc](https://www.sec.gov/Archives/edgar/data/1833214/000143774923014291/filename1.htm#:~:text=RE%3A-,SAB%20Biotherapeutics%2C%20Inc.,-Registration%20Statement%20on). Registration Statement on **Form S-3** **File No. 333-271768** **Filed May 9, 2023"** The S-3 is a shelf registration. The S-1 that the [registration was withdrawn](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-267012&owner=exclude&count=40) was from August 2022. Think perhaps SABS decided to go with the S-3 shelf registrations, rather than that S-1. A [different S-3 was filed February 3](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-269565&owner=exclude&count=40) and effective February 10.
I was heavily stalking the BIO conference in Boston last week for my DNA. sABS was there, too. Biggest international bio convention in the world. Ten thousand companies presenting. SABS explicitly pitched for partnering and out licensing. That could be another reason to clean up the shelf. https://ir.sab.bio/investor-relations/ it is in Eddie’s first minute of the video presentation from BIO Boston.
Ya. I don’t really know, but if you are SABS and someone is looking to buy a piece of you, I think you would want the unused offering to be closed and deleted. Or, in my wildest imagination, maybe you would want to be very clear about the float size to attract more investors if you were on the edge of a breakthrough. It’s just weird because they are down to the dregs of their cash. I mean they run a tight ship and all, but have about 8 milly left last I checked.
I can’t believe I have entered SABS commons, again. But I did just buy that dip. I’m also taking a position in PRST …definitely on a weird pump in Eastern Europe. Massive tweet fest coming out of Belgrade. Couldn’t resist that one either.
SABS is speaking at the BIO 2023 International Convention at 3:45 pm. I’m not sure they have anything new to share as such, but just in case. One thing that I noticed is that they mention that “…SAB is seeking out-licensing and partnering opportunities for SAB-176 and SAB-185 programs.” They’re looking for revenue/funding and this maybe the place to find deals? https://ir.sab.bio/news-releases/news-release-details/sab-biotherapeutics-present-novel-human-igg-platform-positive
Only 2,000 volume on SABS warrants. Any major selling will push down to 5 cents pretty quickly and that’s where I will come in ayy lmao
Apologies to my SABS homies for the murder today. I’ve been selling a decent chunk of warrants above 10 cents. I don’t think the warrants should trade above 10% of common price and I’m getting a feeling shares will drop once they get shelf offering going. Then they’ll probably reverse split to keep share price above the $1 mark. I sold a few thousand commons shares last week as well anticipating these headwinds. My thought process is I’ll buy back later when there is more reason to attempt to hold up share value. Unfortunately management doesn’t seem interested in keeping shares above $1 to avoid the split- likely because they need money via dilution instead of debt. I’ll be quite sad if they don’t manage to get a partnership or if they are forced to sell out for pennies on the dollar. Owners/C-suite team are still big holders of shares so they feel the sting just as much if not more than the rest of us.
>Am I reading that right? Don't think so. That S-3 says: "[As of May 5, 2023, the aggregate market value](https://www.sec.gov/Archives/edgar/data/1833214/000143774923013303/sabs20230504_s3.htm#:~:text=As%20of%20May%205%2C%202023%2C%20the%20aggregate%20market%20value) **of our outstanding common stock** ***held by non-affiliates*** pursuant to General Instruction I.B.6 of Form S-3 **was approximately $31.1 million**, which is based on 35,843,245 shares of common stock held by non-affiliates as of such date and a price of $0.87 per share, the closing price of our common stock on May 5, 2023. Pursuant to General Instruction I.B.6 of Form S-3, **in no event will we sell securities** registered on the registration statement of which this prospectus is a part **with a value of more than one-third of the aggregate market value of our common stock** ***held by non-affiliates*** **in any 12-month period**, so long as the aggregate market value of our common stock held by non-affiliates is less than $75 million. " So that says SABS cannot sell more than around $10 million worth of shares in a 12 month period ( 1/3 of $31.1 million, actually ) while the ***market value held by non-affiliates*** is < $75 million. That S-3 isn't effective yet. The other S-3 they [filed on May 1st](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-271543&owner=exclude&count=40) ***is*** now effective. That one is to sell 300,000 shares. That is from the "2023 Ladenburg Agreement", announced March 24. Ladenburg received a warrant to purchase 300,000 shares at $0.5424 per share, and those shares are now registered for public sale. In addition, "[Pursuant to the terms and subject to the conditions set forth in the 2023 Ladenburg Agreement](https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/sabs20230324_8k.htm#:~:text=Pursuant%20to%20the%20terms%20and%20subject%20to%20the%20conditions%20set%20forth%20in%20the%202023%20Ladenburg%20Agreement), the Company will (i) **no later than June 30, 2023, pay $1.5 million to Ladenburg in cash or shares of common stock**, at the Company’s option; and (ii) **no later than December 31, 2023, pay $1.1 million to Ladenburg in cash or shares of common stock**, at the Company’s option."
Ya it’s weird they are recycling remnants, but if they are getting results published on DoD work, I think there are additional reviews before submission. They should be doing more PR, so I’ll take! Heck, they should publish all the early Mers work from their inception! Elsewhere, Gingko started a collaboration to run more efficient clinical trials and partnered with Kroger on it. After watching SABS languishing while their CROs used AIDs clinics to run their trials, I am holding more knowledge than I ever thought possible on how to reform the decrepit system, safely of course. SABS would be through all of this if the system were not so dysfunctional for the clinical trials.
Anyone who understands shelf filings could you look at SABS shelf filing? It says pretty early on in their S-3 prospectus that they won’t sell any shares or anything if market cap is under $75 million. Am I reading that right? So they have to push market cap above $75 million before sales and then they can only sell $50 million in securities right?
[SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies](https://www.globenewswire.com/news-release/2023/05/12/2667793/0/en/SAB-Biotherapeutics-Announces-First-Publication-of-Promising-Nonclinical-Data-for-SAB-183-Against-Pneumonic-Plague-in-the-Journal-Antibodies.html) \- SABS SABSW "This publication marks the first study data that have been announced for SAB-183."
SABS with a shelf registration filing to sell up to $50m in additional stock. Kind of expected, let’s hope they need as few shares as possible to manage liquidity. https://www.sec.gov/Archives/edgar/data/0001833214/000143774923013303/sabs20230504_s3.htm “From time to time, we may offer and sell up to an aggregate of $50,000,000 of any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. We may also issue units comprised of one or more shares of common stock, shares of preferred stock, debt securities, warrants and/or rights in any combination.” “USE OF PROCEEDS - Unless otherwise indicated in the prospectus supplement, we will use the net proceeds from the sale of securities offered by this prospectus for development and commercialization of product candidates, working capital, and general corporate purposes. In addition, we believe opportunities may exist from time to time to expand our current business through acquisitions or in-licenses of, or investments in, complementary companies, medicines, intellectual property or technologies. While we have no current agreements or commitments for any specific acquisitions, in-licenses or investments at this time, we may use a portion of the net proceeds for these purposes. As of the date of this prospectus, we have not identified any specific and material proposed uses of the anticipated proceeds.”
The only ticker I’ve been shilling for years. SABS
SABS spiked and back to it’s normal sub $1.00 price. Is this a case of existing news being seen as new news, or was the information below not shared up til now? https://www.reddit.com/r/Spacstocks/comments/137jytr/sab_biotherapeutics_presents_positive_phase_1_and/?utm_source=share&utm_medium=ios_app&utm_name=ioscss&utm_content=1&utm_term=1
Someone is going balls deep on SABS warrants today and I’m proud to report it isn’t me for once!
SABS up a casual 35% on above average volume. Probably nothing.
All in SABS not serious Kinda serious
SABS - posts positive data from phase 3 trial of SAB-185 in patients with COVID-19. CMND - up on patent application for depression treatment.
[SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications](https://www.globenewswire.com/news-release/2023/04/26/2655066/0/en/SAB-Biotherapeutics-Announces-Positive-Results-from-Phase-3-Trial-of-SAB-185-in-Patients-with-COVID-19-at-High-Risk-for-Severe-Complications.html) \- SABS SABSW <sigh> If only this press release was issued two years ago ...
SABS gonna try and get out from deficiency status without reverse split or extraordinary measures. Hopefully they can follow up with one more piece of decent news to lock in share price above $1 for awhile. 35m shares traded hands today is pretty solid. I’m hoping there will be some filings from institutions in the next while showing more interest now that they have some legitimacy in something aside from Covid treatment. They have an insanely robust pipeline and if one treatment is considered a breakthrough why won’t all the others when SABS is the only company capable of generating polyclonal antibodies? Only downsides are their past inability to create sensible trial parameters that decimated their Covid trial and treatment as a whole. The other is only having cash on hand to continue operations through year end 2023.
I have warrants. I mostly want warrants of all my holdings. However, for a few that I like, if the commons get under $2, I start to buy commons instead, because I start to imagine scenarios like the commons going to $9 in 4 years which is still an amazing return, but would make my warrants worthless in the end. I have now implemented this for $STRC, $TMPO, $SABS, $SNAX, $DNA, and maybe a couple more I'm forgetting.
[SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy](https://www.globenewswire.com/news-release/2023/04/18/2648996/0/en/SAB-Biotherapeutics-Announces-U-S-FDA-Grants-Breakthrough-Therapy-Designation-to-SAB-176-Influenza-Immunotherapy.html) \- SABS SABSW
$SABS up over $1 today, 40% gain and huge volume on some approval news.
Ya, I had only a couple hundred commons and went to cash on a loss on them. But I still have an ungodly amount of SABSW and averaged down doggedly. So I’m happy to see it move. The fast track was good news. The TAM on the flu therapy is pretty huge. Big problem. Getting worse. I’ve always liked SABS and I was just getting ready to capitulate and move on, so that’s good to have a little action.
No problem, just curious. In 2023 I've only been dribbling into SABS instead of SABSW, so I'm almost back to break even on my commons.
SABS just got fast track status for their influenza treatment. I’d rather their C. Diff treatment get fast tracked, but hopefully both can get it.
You think you feel silly about SABS? I don’t want to know how much loss I’ve taken from them… I sold like 5% of my holdings to 0 out my gains for 2022(oil gains/option writing premiums from above holdings). They are a big fat bust and I still have deep 6 figures of warrants for them lmao
Ya. At least it didn’t tank grossly on earnings last week. I’m sure you know how I feel about SABS. 😅🤡
I’ve been adding Payo and sofi both when under $5 and still have a nice mix of CC and CSP on both. Got roughly 2,000 shares of each and like em both. Payo sits on lots of other peoples cash so as interest rates creep up so does their interest income. They are expanding rapidly in developing countries like China and India which both have solid opportunities and potential instead of trying to enter a crowded US market. Their fee structure is lower than competitors but helps their growth a lot. Valuation below $10 seems awesome and they crush their charts for estimated growth from when they were merging to go public. If only the 3rd leg of my SPAC trio SABS was doing so well lmao
Huge utility in London and ZNTE now EVEX has those contracts enmeshed with their helo operations that are used quite a bit. Also it’s totally normal in Brazilian cities to have helo taxis. 30% of market share is Brazil and LatAm. Already a habit in those regions for conventional helos. The e-vtol is just going to piggyback on that. No less than two vertiports( eVTOL hubs) have been created in Florida. It’s pretty mind boggling. https://www.nytimes.com/2020/11/11/business/flying-car-vertiport.html https://tavistockdevelopment.com/project/lilium-lake-nona-vertiport/ I should not have capitulated on my EVEX, and bought SABS. Lololol 😅😂🤡🍿
Still holding on to my SABS warrants, probably till they expire or, worst case fold when they run out of money. They’ll have to either find new funding, or some magic revenue stream or I don’t know how they stay in business.
Amazing! What a beautiful world. Rob Parks and a few others are in it. You can search r/spacs for the history of SABS. I’m in both warrants and commons. I’m envious of your entry point. Very lovely 😊 busiest day of my life today with a big interstate move. But wanted to acknowledge the importance of adding some more decent folks to the SPAc family and to say it was worth slumming it with the murder hornets in the middle of the night yesterday because you found us! We are your kinda people. Very positive to hear from you!
You piqued my interest the other day so I dipped my toes in the water with some SABS. I got into some NewLink years ago and that was a fun ride, so why not? :).
Sofi and payo doing well enough for me. SABS could try a little harder lol they just got their delist notice.
So, I have a well researched reply. The whole basket of biotech simply must abandon a spray and pray approach to drug pipelines at this point. What are your key revenue generating priorities and how can you set your lessers on the shelf. I previously explained that the ARPA-H money train would only ever be granted to companies that had a prior record of activity in Phase three. This was a Venn diagram overlapping set of (laborious time on c-Span in the summer listening to every hearing and reading every transcript or document) and I personally concluded that SABS had done the correct thing by achieving stage three on Covid drug, but needed to pivot and be highly effective in a critical area with a larger sustained target population. Accordingly they have dumped COVID revenue and moved into type one diabetes treatment, oncology, and c-diff. Three areas that without them have few treatments that are efficacious. Also, the science is interesting in that they have a certain cure, and it comes before catastrophic outcomes if administered in an onset or prophylactic manner. I remain bullish and care not about sunset ing or shelves such NAT SEC cures as Ebola, MERs, and Covid. The gal from Vladivostok gets it. Have one or two in the late stage fast track pipeline. Execute. This is a little explanation to cement m my y thesis https://twitter.com/bradloncar/status/1612928476293787650
SABS closes out their DoD contract and gets about 8.2 million dollars to carry them through all operating expenses through end of 2023. https://www.globenewswire.com/news-release/2023/01/18/2590857/0/en/SAB-Biotherapeutics-Receives-an-Additional-8-2-Million-in-Closeout-of-DoD-Contract.html
SABS good stuff https://finance.yahoo.com/news/sab-biotherapeutics-novel-diversitab-platform-130000042.html
Watching that nested XWEL Concentric Ginkgo airport testing like a hawk. A part of me thinks: .35 cents, worth the gamble. Then bc other part of me thinks that I should stick to my thesis and just buy more disappointing SABS with that lunch money. Both going to get some some gains by catalyst around 15.1.2023. Just don’t have the heart to pull the trigger. Cash fang apathy. Struggle is real.
If anyone wants out of their SABS warrants someone is buying a metric F-ton at 5.5 cents
Honestly almost every small biotech fails. Having a brilliant product is literally only 5-10% of the battle. Having management that is capable of getting intelligent trial studies designed and executing on passing phases 1-3 is 40% of the fight, getting it done before other competitors get their products on the market first is 20%, and the remaining 30% is marketing and getting coverage from formularies so people can actually access it is the last part. I wouldn’t recommend buying a company unless they have products through all 3 phases and actively on the market. Signed guy with giant bags of SABS.
Truly, the worst investor in this sub. DNA and SABS for life, jeez.
Good morning 🌞 I am feeling like the SABS capital raise is not too bad, not great, but it seems legit and not likely to impact the execution of the warrant agreement. If it gives them more time to get a product to market as they sold everything to insiders and privately, so be it. Stay afloat, avoid delisting, and get through the approval process. It is actually quite nice that they had enough takers to make it work privately.
So what I think you are referring to is crescent terms where the exercise price & redemption price is reduced? The key thing with these is they only apply to additional capital raised in connection with the initial business combination. Any shares issued in a capital raise after the business combination have no effect on the warrants. The relevant info in the [warrant agreement](https://www.sec.gov/Archives/edgar/data/1833214/000149315221000441/ex4-4.htm) for SABS is in section 4.3.2 >*If (i) the Company issues additional shares of Common Stock or securities convertible into or exercisable or exchangeable for shares of Common Stock for capital raising purposes* ***in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Common Stock****, with such issue price or effective issue price to be determined in good faith by the Board (and in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by such holder or affiliates, as applicable, prior to such issuance) (the “New Issuance Price”), (ii) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation thereof (net of redemptions) and (iii) the volume weighted average trading price of the Common Stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the Warrant Price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the New Issuance Price and the Redemption Trigger Price (as defined below) shall be adjusted to equal to 180% of the higher of the Market Value and the Newly Issued Price.*
SABS raised $8 million with private placement of warrants and shares… does that affect the $11.50 price for previous warrants or does that have no affect on the public warrants?
They got one. I remember from SABS it takes about six months and can be appealed and you only need ten days above $1 to get out of the predicament. If SABS can do it, just about anyone can. SABS came back from about .70 cents, too.
As of this morning I am in BSGAR , ARIZR, SABSW, SABS commons, DNA commons. I flipped all the DNA warrants on gains over a year to acquire more commons and DCA down. I’m still at at $3 CB because it is not easy to lower your CB in a minnows port if you have more than 20,000 shares of anything. It is not very flattering but other than the ARIZR, I feel like my tickers have a big upside and I’m not stupid, they will suck royally for 12-18 months. My biggest risk is boredom to be frank.
I'm not sure exactly what you mean by that. I'm not playing for today's pump, I'm holding long term. Looking at $DNA, $STRC, $SABS, especially $BKSY, in my portfolio. Both BKSY and ACEV warrants were about 0.17 yesterday, BKSY commons $1.70. If TMPO stays above that, warrants should go up. Which means I won't get a better entry in TMPOW than I had in ACEVW the past few weeks.
SABS had a partnership in research with CSL Behring. Not sure if they still do. But CSL Behring just was approved by the FDA for the most expensive drug in history. A gene therapy for hemophilia B. It costs $3.5 million a dose. It’s nice to see an intravenous genetic component drug get such positive results. https://menafn.com/1105221295/US-Food-And-Drug-Administration-Approves-CSLs-HEMGENIX-Etranacogene-Dezaparvovec-Drlb-The-First-Gene-Therapy-For-Hemophilia-B
SABS just dropped an updated corporate presentation https://www.sec.gov/Archives/edgar/data/1833214/000095017022025544/sabs-ex99_1.htm
Glad it was useful. I guess my weird fascination with the DRC (Ebola SABS) makes more sense now and my commitment to SAI during the Kazakh crisis has been justified. Still trading better than SNAX and DNA. SMH. The folks who hate government services perplex me. I have exactly one possession that I never competed for and struggle to deserve: munis passport. Hottest commodity ever I lucked into by a genetic lottery. 😉 would defend it to death. I’m so lucky
SABS maintaining $1.10 ish. Could get off delisting probation.
SABS and SABSW have given a report on Q3. I guess they are waiting on about 6 million income to be settled out from the prior DOD grant. They restated their cash on hand is sufficient to make it through July 2023. So, no surprises and it has stabilized over the $1 threshold for now. So that’s good. Still a little choppy but back in the game. 💪
Anyone in that Houston Nautical Robotics firm? Looks very parallel to SABS with trust size, market cap, revenue, cash to burn, and guaranteed contracts from research in defense-even though SABS unwound those.
Micro caps generally seem to be rebounding hard. Snax have almost x2 from the $0.25 cent shares I bought. I would be so hyped if SABS got a solid deal or more partners and rocketed. Even if warrants approached $0.50 I’d be hyped
SABS up to 1.23 (8%) on 120k volume (twice the average).
Ok I am out, how can you be running late if you woke up five hours ago? 😬 I love Morgan Stanley and when Mike Wilson, their equities strategist, said: what do you want want to hold for two years? I could relate. We should have a free for all on that. WHAT DO YOU WANT TO HOLD FOR TWO YEARS? Who cares what I want to hold, but for me it is ORGNW, MSTR at $80, BSGAR and ARIZR, SABS and DNA commons. I am also thinking ASTS is interesting but I was never popular, but I was accepted by every In group, and the twitter furus strike me as high school dynamics. I am hang with them without committing to their group think. What are you holding for two years? I am out. Catch y’all on the other side.
Ya, happened to SABS. They have been above a dollar for about a week now, so there’s hope. It was grim when the deficiency notice was used. But when I looked it up, one can also appeal for an extension if they have a good plan. So technically it could be a long time before some of these delist.
Good morning from hurricane central. I had fitful sleep between the termite disclosure on the house I am under contract on and my SPAClife…and the outrageous gusts of howling winds… well I dreamt that Eddie Sullivan from SABS asked me to handle that presentation to potential customers and buyers up in Boston on 17 November. Weird. My first thought is this cannot be good for my warrants. My next thought was that I might do a better job than Eddie and I woke up disoriented. 😳😅
Quietly building SABS under the radar, polyclonal antibodies has a future. LTRPA and TRIP are looking nice after a earnings miss beatdown. I bet they crush next earnings. Entry in LTRPA in the .80s is unreal. Made nearly 100% on my last entry at .78. I am convinced the projections were skewed to allow HF to loadup near all time lows yet again. Yoy they crushed but missed EPS because of currency exchange rates...? Really? Miss by 30 million and 1 billion gets swiped of the market cap? This market is unreal.
Ps $SABS looking good 👍 and might be shopping for partnerships according to recent press release for a networking event in their field for VC investment that looks promising. I always have to remind myself that they had enough cash last ER to cover operations for a year. Shaky, but probably going to be ok.
Dang. Glad I got too busy with real estate shenanigans to post on my DNA thesis. Because Monday she shat the bed. I went ahead and bought another 1000 shares at the $2.40 mark. If it gets close to $2.10 again, I will load again. I have always felt it was worth it from $2.40-$3.40. Obviously, $2.40 being more optimal. $2.09 is all-time low. Earnings next Monday AH. Went back into the $2.60s today for a while so I didn't feel dumb. ;) ...Jason in Japan, the list of partners is so stellar, it can't be beat-- Sumitomo, Bayer, Roche, etc. Just dead cash for a while for me, maybe 2-3 years. SABS came back to life the minute I stopped fretting about it. ;) Down to a $3.17 average on $DNA and that's getting better. Lots of free shares from flipping it ATH. Shrugs shoulders. Bid on a $300k house. Got them down to $270k. Now for the DD and inspections next ten days. Close to an acre. Lot's of light. Shitty kitchen. lol. New HVAC, roof, H2o heater. Shrugs shoulders. I voted. That's about it... have a good day.
SABS shares getting some traction? Pretty strong movement above $1
SABS dropped more clinical info about their platform showing viability and proving their management is just incompetent for not being able to utilize their capability. Hopefully buyout coming LOL
Wow. Super grateful for the kind welcome back. You guys are amazing. Folks who haven't seen me post on $DNA for two years running asked why I am in it. Good news is, I'm in a three week module in my teaching on Syn Bio, and so should be able to do a recap of the DD for the weekend main area with some great links and I'm I busy do it shouldn't be too verbose. Mostly, I am just so grateful. Bis on another 200 shares. Just have to play lunch money these days. I look at my major fuckups. ZNTE $19K and SABSW another $19K and haven't even fully exited the SABSW-lolol. I'm still sitting on 10K SABS warrants. Jebus! But if we look back to pandemic. I had $4000 -never even thought about investing, read about SRAC, thought WTF is a blank check, and well it has been a weird road. I have lost 40K. But if I get really real. I started with $4k. So fuckit. Ilove you guys. I keep acting like I am losing money. I am most definitely NOT! ... I mean if we look at the whole situation. Remember, I'm a wage slave plebe, fucked up with student loan debt, lived paycheck to paycheck my whole life while working anywhere from three to 8 jobs. r/SPACS is my miracle. Literally a fucking miracle I found you and then the fact that you tolerate me (sorta) is golden. Currently bidding on some very weird and very big properties and doubling down on a vision to house Ukranian (mostly ladies and their children while their husbands serve) refugees in Georgia, where I have community connections through my PhD in violence studies. Sure, I'm financially a newb, but what y'all have taught me will never go to waste. Admittedly, I might not ever get out of the hole dug by decades of financial ignorance aka debt, but as I rise, I have committed to rise in tandem with folks who have even less $$$ than myself. I think I got this. ;) Elsewhere, that powerball is too weird not to buy. Do it. Makes me sad tho, as when meritocracy fails, one goes to the lottery. Deep game theory includes, wait for it, DNA in game theory. Meaning, when the lottery becomes most popular, it means meritocracy has died and DNA, or inherited wealth, has climbed so far that merit, entrepreneurship, and effort will not create wealth. Those lotteries will only get bigger and more important in our lifetimes. I did a PhD in *historical* game/war theory from Johan Huizinga to Roger Caillois. Trust me, when that lottery hits 1.5 billion, we got a social situation, as a humanist it is utterly mind boggling to see it play out in my new hobby of macro econ. There is no distinction in game theory between war and play, just FYI. ;) Have a great day... coupla rabbit holes for you: [https://en.wikipedia.org/wiki/Roger\_Caillois](https://en.wikipedia.org/wiki/Roger_Caillois) [https://en.wikipedia.org/wiki/Johan\_Huizinga](https://en.wikipedia.org/wiki/Johan_Huizinga) Mwah, love you guys. Cannot wait to post a final home buy, just may take another 6-8 weeks. Prepare those SNAX memes, I'm buying in based on the quality of the memes. ;) Solidarity, as always.
$SABS and $SABSW Does this mean anything, until they get their phase 2a and phase 3 successfully completed? https://www.globenewswire.com/news-release/2022/10/27/2542825/0/en/SAB-Biotherapeutics-Announces-Exclusive-Manufacturing-Partnership-with-Emergent-BioSolutions.html
I think SABS won't go to 0 because of "national defense".